PPARα agonist WY-14,643 induces adipose atrophy and fails to blunt chronic ethanol-induced hepatic fat accumulation in mice lacking adipose FGFR1

Biochem Pharmacol. 2021 Oct:192:114678. doi: 10.1016/j.bcp.2021.114678. Epub 2021 Jul 13.

Abstract

Fibroblast growth factor 21 (FGF21) is mainly regulated by peroxisome proliferator-activated receptor α (PPARα) in liver. The PPARα-FGF21 axis protects against alcohol-related liver disease (ALD). FGF21 exerts its effect via FGF receptor 1 (FGFR1). However, liver specific FGFR1 abrogation had no effect on ALD. Adipose tissues highly express FGFR1. When adipocyte specific FGFR1 knockout (fgfr1adipoQ-cre) mice and corresponding normal control (fgfr1fl/fl) mice were fed with Lieber-DeCarli ethanol liquid diet for 3 weeks, liver triglyceride (TG) accumulation was increased in the fgfr1fl/fl mice to a greater extent than in the fgfr1adipoQ-cre mice. When PPARα agonist WY-14,643 was added in the liquid ethanol diet at 10 mg/L, the ethanol-induced liver TG accumulation was blunted in the fgfr1fl/fl mice but not in the fgfr1adipoQ-cre mice. There was no significant difference in WY-14,643-induced fatty acid oxidation, ethanol metabolism, and oxidative stress between the fgfr1fl/fl and fgfr1adipoQ-cre mice. Interestingly, adipose atrophy was induced by WY-14,643 in the fgfr1adipoQ-cre mice but not in the fgfr1fl/fl mice. Serum free fatty acid was also decreased by WY-14,643 in the fgfr1adipoQ-cre mice but not in the fgfr1fl/fl mice. These results suggest that WY-14,643 inhibits alcoholic fatty liver and regulates adipose tissue mass and fat mobilization from adipose tissues to liver in an adipocyte FGFR1-dependent manner.

Keywords: ALOX5; COX2; Fibroblast growth factor 21 (FGF21); GPX4; Oxidative stress; iNOS.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adipose Tissue / drug effects*
  • Adipose Tissue / metabolism
  • Animals
  • Atrophy / chemically induced
  • Atrophy / metabolism
  • Ethanol / administration & dosage
  • Ethanol / toxicity*
  • Fatty Liver, Alcoholic / metabolism
  • Fatty Liver, Alcoholic / prevention & control*
  • Female
  • Mice
  • Mice, Knockout
  • PPAR alpha / agonists*
  • PPAR alpha / metabolism
  • Peroxisome Proliferators / therapeutic use
  • Peroxisome Proliferators / toxicity
  • Pyrimidines / therapeutic use*
  • Pyrimidines / toxicity
  • Receptor, Fibroblast Growth Factor, Type 1 / deficiency*
  • Receptor, Fibroblast Growth Factor, Type 1 / genetics

Substances

  • PPAR alpha
  • Peroxisome Proliferators
  • Pyrimidines
  • Ethanol
  • pirinixic acid
  • Fgfr1 protein, mouse
  • Receptor, Fibroblast Growth Factor, Type 1